The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Osadchuk M.A.

Federal State Autonomous Educational Institution of Higher Education «I.M. Sechenov First Moscow State Medical University» of the Ministry of Healthcare of the Russia Department of Polyclinic Therapy of the Faculty of Medicine, Moscow, Russia

Solodenkova K.S.

Department of Outpatient Therapy, Medical Faculty of Sechenov First Moscow State Medical University, Russian Ministry of Health, Moscow, Russia

Mediators of inflammation: the role in development of vascular lesions and cardiovascular risk evaluation

Authors:

Osadchuk M.A., Solodenkova K.S.

More about the authors

Journal: Russian Journal of Cardiology and Cardiovascular Surgery. 2016;9(4): 63‑72

DOI: 10.17116/kardio20169463-72

Read: 8050 times

Download PDF (RU)
Contact the author
Table of contents

MEDIATORS OF INFLAMMATION: THE ROLE IN DEVELOPMENT OF VASCULAR LESIONS AND CARDIOVASCULAR RISK EVALUATION
MEDIATORS OF INFLAMMATION: THE ROLE IN DEVELOPMENT OF VASCULAR LESIONS AND CARDIOVASCULAR RISK EVALUATION

To cite this article:

Osadchuk MA, Solodenkova KS. Mediators of inflammation: the role in development of vascular lesions and cardiovascular risk evaluation. Russian Journal of Cardiology and Cardiovascular Surgery. 2016;9(4):63‑72. (In Russ.)
https://doi.org/10.17116/kardio20169463-72

ЭндоКард
Подписка 2026 Кардиология и сердечно-сосудистая хирургия (Russian Journal of Cardiology and Cardiovascular Surgery)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
On the path to personalized cardiology: prospects of precise asse­ssment of cardiovascular risks and predictive-prognostic diagnostics. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(2):206-215
Two years expe­rience of using alirocumab in patients with dyslipidemia. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(2):216-220
The role of quantitative body composition analysis in popu­lation in the asse­ssment and moni­toring of cardiovascular risk meta­bolic factors. Russian Journal of Preventive Medi­cine. 2024;(12):128-134
Exploring the capa­bility of the cardiovascular risk evaluation using the vital functions inte­gral analysis. Russian Journal of Preventive Medi­cine. 2025;(3):53-59
Prevalence and role of elevated serum lipo­protein(a) in patients with myocardial infa­rction acco­rding to the Russian regi­ster of acute myocardial infa­rction REGION-MI. Russian Cardiology Bulletin. 2025;(1):39-48
The place of non-high-density lipo­protein cholesterol and triglycerides in the asse­ssment of cardiovascular risk: Reso­lution of the Panel of Expe­rts. Russian Journal of Preventive Medi­cine. 2025;(4):7-15
Creating an index reflexing cardiovascular risk using the vital functions inte­gral analysis. Russian Journal of Preventive Medi­cine. 2025;(4):82-88
QRISK-3 cardiovascular risk asse­ssment algo­rithm in prediction of kidney transplantation outcomes. Russian Cardiology Bulletin. 2025;(2):61-69
The Webiomed.DHRA deci­sion-making support system for medi­cal examinations in the Russian Fede­ration: a cost-effectiveness analysis. Medi­cal Technologies. Asse­ssment and Choice. 2025;(3):61-73
Abstract:

Keywords:

mediators of inflammation
cardiovascular risk

Authors:

Osadchuk M.A.

Federal State Autonomous Educational Institution of Higher Education «I.M. Sechenov First Moscow State Medical University» of the Ministry of Healthcare of the Russia Department of Polyclinic Therapy of the Faculty of Medicine, Moscow, Russia

Solodenkova K.S.

Department of Outpatient Therapy, Medical Faculty of Sechenov First Moscow State Medical University, Russian Ministry of Health, Moscow, Russia

Close metadata

References:

  1. Gurevich V.S. Modern understanding of the atherosclerosis pathogenesis. Bolezni serdtsa i sosudov. 2006;4:4-8.(in Russian)
  2. Moiseev V., Meraj I., Pavlikova E., Moiseev V. The role of inflammation in the processes of atherogenesis and in the development of cardiovascular events. Vrach. 2003;3:3-6.(in Russian)
  3. Nagornev V.А., Voskan'yants А.N. Atherogenesis as immunoinflammatory process. Vestnik RАMN. 2004;7:3-11.(in Russian)
  4. Gusev D.E., Potievskij B.G., Rajchevich N., Syrkin А.L. Inflammatory markers in various forms of ischemic heart disease. Kardiologiya i serdechno-sosudistaya khirurgiya. 2012;5(4):4-8.(in Russian)
  5. Kulikova А.N. The role of inflammation in atherogenesis in diabetes mellitus (literature review). TSitokiny I vospalenie. 2007;3:14-19.(in Russian)
  6. Ponomar' E.G., Syrkin А.L., Gusev D.E., Аndreev D.А. Inflammatory markers and long-term prognosis in patients with acute coronary syndrome and stable form of coronary heart disease. Kardiologiya i serdechno-sosudistaya khirurgiya. 2011;4(6):10-15.(in Russian)
  7. Syrkin А.L., Novikova N.А., Terekhin S.А. Ostryj koronarnyj sindrom. M.: MIА. 2010.(in Russian)
  8. Zarubina E.G., Mishina E.А., Osadchuk M.А. The role of endothelial dysfunction in the pathogenesis of combined cardiopulmonary diseases. Klinicheskaya meditsina. 2006;84(5):31-37. (in Russian)
  9. Janet S-B, Nancy W, Elizabeth M-D, et al. Inflammatory markers are increased in youth with type I diabetes: the SEARCH casecontrol study. J Clin Endocrinol Metab. 2010;95(6):2868-2876. doi: 10.1210/jc.2009-1993
  10. Lin J, Glynn RJ, Rifai N, Manson JE, Ridker PM, Nathan DM, Schaumberg DA. Inflammation and progressive nephropathy in type 1 diabetes mellitus in the Diabetes Control and Complications Trial (DCCT). Diabetes Care. 2008;31:2338-2343. doi: 10.2337/dc08-0277
  11. Wedrychowicz A, Dziatkowiak H, Sztefko K, Wedrychowicz A. Interleukin-6 (IL-6) and IGF-IGFBP system in children and adolescents with type 1 diabetes mellitus. Exp Clin Endocrinol Diabetes. 2004;112:435-439. doi: 10.1055/s-2004-821189
  12. Simbirtsev А.S. Cytokines - classification and biological functions. TSitokiny i vospalenie. 2004;3(2):16-22. (in Russian)
  13. Hartge MM, Unger T, Kintscher U. The endothelium and vascular inflammation in diabetes. Diab Vasc Dis Res. 2007 Jun;4(2):84-88. doi: 10.3132/dvdr.2007.025
  14. Dedov I.I., SHestakova M.V. Sakharnyj diabet. M.: Universum Pablishing. 2003.(in Russian)
  15. Voskan'yants А.N., Nagornev V.А. Proliferation of human artery wall cells in atherogenesis as a factor of immune inflammation. TSitokiny i vospalenie. 2004;3(4):10-13.(in Russian)
  16. Simbirtsev А.S. Cytokines - a new system of regulation of the body's reactions. TSitokiny i vospalenie. 2002;1(1):9-17. (in Russian)
  17. Biasucci LM, Liuzzo G, Fantuzzi G, et al. Increasing levels of interleukin-1 Ra and interleukin-6 during the first two days of hospitalisation in unstable angina are associated with increased risk of in-hospital coronary events. Circulation. 1999;99:2079-2084. doi: 10.1161/01.CIR.99.16.2079
  18. Rosa JS, Flores RL, Oliver SR, Pontello AM, Zaldivar FP, Galassetti PR. Sustained IL-1alpha, IL-4, and IL-6 elevations following correction of hyperglycemia in children with type 1 diabetes mellitus. Pediatr Diabetes. 2008 Feb;9(1):9-16. doi: 10.1111/j.1399-5448.2007.00243.x
  19. Babaeva А.R., Tarasov А.А., Bezborodova T.А., Zakhar'ina O.А. The concept of systemic inflammation in the pathogenesis of diabetic angiopathy. Vestnik Volgogradskogo gosudarstvennogo meditsinskogo universiteta. 2010;1:3-8.(in Russian)
  20. Gotsman I, Stabholz A, Planer D, Pugatsch T, Lapidus L, Novikov Y, Masrawa S, Soskolne A, Lotan C. Serum cytokine tumor necrosis factor-alpha and interleukin-6 associated with the severity of coronary artery disease: indicators of an active inflammatory burden? Isr Med Assoc J. 2008 Jul;10(7):494-498.
  21. Babaeva А.R., Sergeeva S.А., CHerevkova E.V., Kostryukova I.V., Klimenko K.S. New possibilities of long-term therapy of inflammatory diseases of the joints. Vestnik Volgogradskogo gosudarstvennogo meditsinskogo universiteta. 2005;4:52-55.(in Russian)
  22. Babaeva А.R., Solodenkova K.S., Sergeeva S.А. The evidence base of anti-cytokine therapy of rheumatoid arthritis. Vestnik Volgogradskogo gosudarstvennogo meditsinskogo universiteta. 2006;4:15-22.(in Russian)
  23. Petrov V.I., CHerevkova E.V., Solodenkova K.S., Babaeva А.R. Innovative aspects of pharmacotherapy of rheumatoid arthritis. Vestnik Volgogradskogo gosudarstvennogo meditsinskogo universiteta. 2012;1:3-9.(in Russian)
  24. CHerevkova E.V., Babaeva А.R., Usacheva M.N., Аleksandrova I.V., Solodenkova K.S. Prognostic markers of rheumatoid arthritis: the possibilities of practical use. Doktor.Ru. 2013;6(84):49-54. (in Russian)
  25. Scholin A, Siegbahn A, Lind L, Berne C, Sundkvist G, Bjork E, Karlsson F. A. CRP and IL-6 concentrations are associated with poor glycemic control despite preserved-cell function during the first year after diagnosis of type 1 diabetes. Diabetes Metab Res Rev. 2004;20:205-210. doi: 10.1002/dmrr.427
  26. Ridker PM. Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT). J Thromb Haemost. 2009;7(Suppl. 1):332-339. doi: 10.1111/j.1538-7836.2009.03404.x
  27. Volpato S, Guralnik JM, Ferrucci L, et al. Cardiovascular disease, interleukin-6, and risk of mortality in older women. The Women`s Health and aging Study. Circulation. 2001;103:947-953. doi: 10.1161/01.CIR.103.7.947
  28. Andersen K, Pedersen BK. The role of inflammation in vascular insulin resistance with focus on IL-6. Horm. Metab Res. 2008 Sep;40(9):635-639. doi: 10.1055/s-0028-1083810
  29. Martens FM, Rabelink TJ, op ‘t Roodt J, de Koning EJ, Visseren FL. TNF-alpha induces endothelial dysfunction in diabetic adults, an effect reversible by the PPAR-gamma agonist pioglitazone. Eur Heart J. 2006 Jul;27(13):1605-1609. doi: 10.1093/eurheartj/ehl079
  30. Kuo LT, Yang NI, Cherng WJ, Verma S, Hung MJ, Wang SY, Liu MH, Chen SY, Wang CH. Serum interleukin-6 levels, not genotype, correlate with coronary plaque complexity. Int Heart J. 2008 Jul;49(4):391-402. doi: 10.1536/ihj.49.391
  31. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011;473:317-325. doi: 10.1038/nature10146
  32. Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, Danesh J. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant metaanalysis. Lancet. 2010;375:132-140. doi: http://dx.doi.org/10.1016/S0140-6736(09)61717-7
  33. Fibrinogen Studies Collaboration, Danesh J, Lewington S, Thompson SG, LoweGD, Collins R, Kostis JB, Wilson AC, Folsom AR, Wu K, Benderly M, Goldbourt U, Willeit J, Kiechl S, Yarnell JW, Sweetnam PM, Elwood PC, Cushman M, Psaty BM, Tracy RP, Tybjaerg-Hansen A, Haverkate F, de Maat MP, Fowkes FG, Lee AJ, Smith FB, Salomaa V, Harald K, Rasi R, Vahtera E, Jousilahti P, Pekkanen J, D’Agostino R, Kannel WB, Wilson PW, Tofler G, rocha-Pinango CL, Rodriguez-Larralde A, Nagy E, Mijares M, Espinosa R, Rodriquez-Roa E, Ryder E, ez-Ewald MP, Campos G, Fernandez V, Torres E, Marchioli R, Valagussa F, Rosengren A, Wilhelmsen L, Lappas G, Eriksson H, Cremer P, Nagel D, Curb JD, Rodriguez B, Yano K, Salonen JT, Nyyssonen K, Tuomainen TP, Hedblad B, Lind P, Loewel H, Koenig W, Meade TW, Cooper JA, De SB, Knottenbelt C, Miller GJ, Cooper JA, Bauer KA, Rosenberg RD, Sato S, Kitamura A, Naito Y, Palosuo T, Ducimetiere P, Amouyel P, Arveiler D, Evans AE, Ferrieres J, Juhan-Vague I, Bingham A, Schulte H, Assmann G, Cantin B, Lamarche B, Despres JP, Dagenais GR, Tunstall-Pedoe H, Woodward M, Ben-Shlomo Y, Davey SG, Palmieri V, Yeh JL, Rudnicka A, Ridker P, Rodeghiero F, Tosetto A, Shepherd J, Ford I, Robertson M, Brunner E, Shipley M, Feskens EJ, Kromhout D, Dickinson A, Ireland B, Juzwishin K, Kaptoge S, Lewington S, Memon A, Sarwar N, Walker M, Wheeler J, White I, Wood A. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant metaanalysis. JAMA. 2005;294:1799-1809. doi: 10.1001/jama.294.22.2848-a
  34. Keavney B, Danesh J, Parish S, Palmer A, Clark S, Youngman L, Delepine M, Lathrop M, Peto R, Collins R. Fibrinogen and coronary heart disease: test of causality by ‘Mendelian randomization’. Int J Epidemiol. 2006;35:935-943. doi: 10.1093/ije/dyl114
  35. Wensley F, Gao P, Burgess S, Kaptoge S, Di AE, Shah T, Engert JC, Clarke R, vey-Smith G, Nordestgaard BG, Saleheen D, Samani NJ, Sandhu M, Anand S, Pepys MB, Smeeth L, Whittaker J, Casas JP, Thompson SG, Hingorani AD, Danesh J. Association between C-reactive protein and coronary heart disease: Mendelian randomisation analysis based on individual participant data. BMJ. 2011;342:d548. doi: http://dx.doi.org/10.1136/bmj.d548
  36. Libby P. Inflammatory mechanisms: the molecular basis of inflammation and disease. Nutr Rev. 2007;65(Pt 2):S140- S146. doi: http://dx.doi.org/10.1111/j.1753-4887.2007.tb00352.x
  37. Danesh J, Kaptoge S, Mann AG, Sarwar N, Wood A, Angleman SB, Wensley F, Higgins JP, Lennon L, Eiriksdottir G, Rumley A, Whincup PH, Lowe GD, Gudnason V. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med. 2008;5:78. doi: 10.1371/journal.pmed.0050078
  38. IL6R Genetics Consortium Emerging Risk Factors Collaboration, Sarwar N, Butterworth AS, Freitag DF, Gregson J, Willeit P, Gorman DN, Gao P, Saleheen D, Rendon A, Nelson CP, Braund PS, Hall AS, Chasman DI, Tybjaerg-Hansen A, Chambers JC, Benjamin EJ, Franks PW, Clarke R, Wilde AA, Trip MD, Steri M, Witteman JC, Qi L, van der Schoot CE, de FU, Erdmann J, Stringham HM, Koenig W, Rader DJ, Melzer D, Reich D, Psaty BM, Kleber ME, Panagiotakos DB, Willeit J, Wennberg P, Woodward M, Adamovic S, Rimm EB, Meade TW, Gillum RF, Shaffer JA, Hofman A, Onat A, Sundstrom J, Wassertheil-Smoller S, Mellstrom D, Gallacher J, Cushman M, Tracy RP, Kauhanen J, Karlsson M, Salonen JT, Wilhelmsen L, Amouyel P, Cantin B, Best LG, Ben-Shlomo Y, Manson JE, vey-Smith G, de Bakker PI, O’Donnell CJ, Wilson JF, Wilson AG, Assimes TL, Jansson JO, Ohlsson C, Tivesten A, Ljunggren O, Reilly MP, Hamsten A, Ingelsson E, Cambien F, Hung J, Thomas GN, Boehnke M, Schunkert H, Asselbergs FW, Kastelein JJ, Gudnason V, Salomaa V, Harris TB, Kooner JS, Allin KH, Nordestgaard BG, Hopewell JC, Goodall AH, Ridker PM, Holm H, Watkins H, Ouwehand WH, Samani NJ, Kaptoge S, Di AE, Harari O, Danesh J. Interleukin-6 receptor pathways in coronary heart disease: a collaborative metaanalysis of 82 studies. Lancet. 2012;379:1205-1213. doi: http://dx.doi.org/10.1016/S0140-6736(11)61931-4
  39. Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium, Hingorani AD, Casas JP. The interleukin-6 receptor as a target for prevention of coronary heart disease: a Mendelian randomisation analysis. Lancet. 2012;379:1214-1224. doi: http://dx.doi.org/10.1016/S2213-8587(15)00034-0
  40. Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1beta inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J. 2011;162:597-605. doi: http://dx.doi.org/10.1016/j.ahj.2011.06.012
  41. Blankenberg S, Luc G, Ducimetiere P, Arveiler D, Ferrieres J, Amouyel P, Evans A, Cambien F, Tiret L. Interleukin-18 and the risk of coronary heart disease in European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation. 2003;108:2453-2459. doi: 10.1161/01.CIR.0000099509.76044.A2
  42. Jefferis BJ, Whincup PH, Welsh P, Wannamethee SG, Rumley A, Lawlor DA, Ebrahim S, Lowe GD. Prospective study of circulating soluble CD40 ligand concentrations and the incidence of cardiovascular disease in a nested prospective casecontrol study of older men and women. J Thromb Haemost. 2011;9:1452-1459. doi: 10.1111/j.1538-7836.2011.04415.x
  43. Welsh P, Whincup PH, Papacosta O, Wannamethee SG, Lennon L, Thomson A, Rumley A, Lowe GD. Serum matrix metalloproteinase-9 and coronary heart disease: a prospective study in middle-aged men. QJM. 2008;101:785-791. doi: http://dx.doi.org/10.1093/qjmed/hcn088
  44. Kaptoge S, Rao Kondapally SS, Gao P, Freitag DF, Butterworth AS, Borglykke A, Di Angelantonio E, Gudnason V, Rumley A, Gordon DO, Lowe, Jorgensen T, Danesh J. Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis. European Heart Journal. 2014;35:578-589. doi: http://dx.doi.org/10.1093/eurheartj/eht367 578-589
  45. Osler M, Linneberg A, Glumer C, Jorgensen T. The cohorts at the Research Centre for Prevention and Health, formerly ‘The Glostrup Population Studies’. Int J Epidemiol. 2011;40:602-610. doi: 10.1093/ije/dyq041
  46. Jefferis BJ, Whincup P, Welsh P, Wannamethee G, Rumley A, Lennon L, Thomson A, Lawlor D, Carson C, Ebrahim S, Lowe G. Prospective study of matrix metalloproteinase-9 and risk of myocardial infarction and stroke in older men and women. Atherosclerosis. 2010;208:557-563. doi: http://dx.doi.org/10.1016/j.atherosclerosis.2009.08.018
  47. Jefferis BJ, Whincup PH, Welsh P, Wannamethee SG, Rumley A, Lennon LT, Thomson AG, Carson C, Ebrahim S, Lowe GD. Circulating TNF-alpha levels in older men and women do not show independent prospective relations with MI or stroke. Atherosclerosis. 2009;205:302-308. doi: http://dx.doi.org/10.1016/j.atherosclerosis.2008.12.001
  48. Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol. 2010;10:301-316. doi: 10.1038/nri2761
  49. Neurath MF, Finotto S. IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer. Cytokine Growth Factor Rev. 2011;22:83-89. doi: http://dx.doi.org/10.1016/j.cytogfr.2011.02.003
  50. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 cells. Annu Rev Immunol. 2009;27:485-517. doi: 10.1146/annurev.immunol.021908.132710
  51. McKellar GE, McCarey DW, Sattar N, McInnes IB. Role for TNF in atherosclerosis? Lessons from autoimmune disease. Nat Rev Cardiol. 2009;6:410-417. doi: 10.1038/nrcardio.2009.57
  52. Navarro-Millan I, Singh JA, Curtis JR. Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor. Clin Ther. 2012;34:788-802. doi: http://dx.doi.org/10.1016/j.clinthera.2012.02.014
  53. Symmons DP, Gabriel SE. Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE. Nat Rev Rheumatol. 2011;7:399-408. doi: 10.1038/nrrheum.2011.75
  54. Dixon WG,Watson KD, Lunt M, Hyrich KL, Silman AJ, Symmons DP. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2007;56:2905- 2912. doi: 10.1002/art.22809
  55. Ridker PM, Howard CP,Walter V, Everett B, Libby P, Hensen J, Thuren T. Effects of interleukin-1beta inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: A Phase Iib Randomized Placebo Controlled Trial. Circulation. 2012;126:2739-2748. doi: 10.1161/CIRCULATIONAHA.112.122556
  56. Hlatky MA, Ashley E, Quertermous T, Boothroyd DB, Ridker P, Southwick A, Myers RM, Iribarren C, Fortmann SP, Go AS. Matrix metalloproteinase circulating levels, genetic polymorphisms, and susceptibility to acute myocardial infarction among patients with coronary artery disease. Am Heart J. 2007;154:1043-1051. doi: http://dx.doi.org/10.1016/j.ahj.2007.06.042
  57. Kinlay S, Schwartz GG, Olsson AG, Rifai N, Sasiela WJ, Szarek M, Ganz P, Libby P. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study. Circulation. 2004;110:386-391. doi: 10.1161/01.CIR.0000136588.62638.5E
  58. Rouy D, Ernens I, Jeanty C, Wagner DR. Plasma storage at -80 degrees C does not protect matrix metalloproteinase-9 from degradation. Anal Biochem. 2005;338:294-298. doi: 10.1016/j.ab.2004.10.052
  59. Kenis G, Teunissen C, De JR, Bosmans E, Steinbusch H, Maes M. Stability of interleukin 6, soluble interleukin 6 receptor, interleukin 10 and CC16 in human serum. Cytokine. 2002;19:228-235. doi: 10.1006/cyto.2002.1961
  60. Grisoni ML, Proust C, Alanne M, Desuremain M, Salomaa V, Kuulasmaa K, Cambien F, Nicaud V, Wiklund PG, Virtamo J, Kee F, Tiret L, Evans A, Tregouet DA. Lack of association between polymorphisms of the IL18R1 and IL18RAP genes and cardiovascular risk: the MORGAM Project. BMC Med Genet. 2009;10:44. doi: 10.1186/1471-2350-10-44
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.